** Shares of drugmaker PTC Therapeutics PTCT.O fall 1% to $54.38
** PTCT says the European Commission has decided not to renew marketing authorization for the company's muscle-wasting disorder drug, Translarna, and that the treatment will no longer be available for sale in the EU
** The drug had received conditional approval in EU in 2014 to treat children aged five years and older who can walk and are afflicted with Duchenne muscular dystrophy
** Company says it plans to work with countries individually to maintain commercial availability of the drug where possible
** TD Cowen analyst Joseph Thome estimates Translarna to generate $192 million in sales for 2025, with a "minimal contribution from the EU"
** Shares have gained 86.8% in the last 12 months, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。